S1P1 Inhibitors
2 drugsAbout S1P1
Sphingosine-1-phosphate receptor 1 (S1P1) is a G protein-coupled receptor crucial for regulating lymphocyte trafficking and immune cell movement throughout the body. Its activation influences immune cell migration, making it a key regulator of immune responses.
S1P1 is a drug target in immunology due to its role in immune cell migration. Currently, there is no genetic evidence directly linking S1P1 to specific diseases, but its involvement in immune cell migration makes it a compelling target.
Two FDA-approved drugs target S1P1: ZEPOSIA (Bristol-Myers Squibb) and VELSIPITY (Pfizer), both small molecules. One S1P1-targeting drug is used in therapeutic areas beyond immunology, suggesting potential applications in other disease areas.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Multiple Sclerosis, Relapsing-Remitting with only 1 trials.
- phase3 represents biological uncertainty with 50% completion.
Top Drugs
Bristol-Myers Squibb and Pfizer are the only companies with approved S1P1-targeting drugs.
Limited competition suggests high barriers to entry or untapped market potential.
Drug Modality Landscape
Modalities
Routes of Administration
S1P1 is amenable to small molecule drugs, with oral options available for convenient dosing.
The modality landscape is underexplored, presenting an opportunity for novel biologics.
Clinical Trials 81 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 23 | 18 | 2 | 3 | 90% |
| Phase 2 | 31 | 19 | 7 | 5 | 73% |
| Phase 3 | 19 | 11 | 5 | 3 | 69% |
| Phase 4 | 8 | 2 | 3 | 3 | 40% |
Top Sponsors
By Modality
Drug Approval Timeline (2020 - 2023)
Relapsing forms of multiple sclerosis (clinically isolate...
The first S1P1-targeting drug was approved in 2020, with the most recent in 2023.
Recent approvals indicate growing interest, but the market may soon become saturated.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 55 clinical trials targeting S1P1.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities